Co-founder and Chief Executive Officer of Nanobiotix
Laurent Levy is the co-founder of Nanobiotix and has served as Chief Executive Officer since March 2003. He was first appointed as Chairman of the Executive Board on May 27, 2004. Laurent has extensive experience in sciences and techniques related to nanotechnologies. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of several concrete applications including Nanobiotix lead product candidate NBTXR3, which could expand therapeutic options and improve outcomes for patients with cancer.
Laurent's mission goes beyond simply curing major diseases like cancer. He and his team are on a mission to unlock humanity's limitless potential or, as they call it, to "Expand Life". From exploring the use of nanotechnology to increase processing power and reshape the brain, to resolving the issues of rapid therapeutic clearance to revolutionize the paradigm of how intravenously administered treatments are designed and delivered--and much more. Mr. Levy's true goal is to help inspire humanity to push beyond boundaries and discover a better way of life. Defeating cancer with the team at Nanobiotix and NBTXR3 is the first step, but only one of many on a bold journey.
From 2000 to 2003, prior to the founding of Nanobiotix, Laurent served as consultant for Altran Technologies and worked in the development of the application of nanotechnologies with companies such as Sanofi S.A., Guerbet S.A., and Rhodia S.A., as well as for early-stage biotechnology companies. He has served as President of the Supervisory Board of Valbiotis S.A. (Euronext Paris: ALVAL) since March 2017, was Vice Chairman of the Executive Board of the European Technology Platform on Nanomedicine (ETPN) from December 2012 to June 2019 and as a founding member of the Nanomedicine Translation Advisory Board (a division of ETPN) from June 2014 to June 2019.
Laurent has authored more than 35 international scientific publications and communications, has applied for and secured several patents, and regularly speaks on the topic of using nanoparticles to fight cancer and other diseases. He holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie; UPVI-ESPCI) in Paris and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives), and a DEA (advanced studies and diplomas) in Physics of Condensed Matter from the UPVI-ESPCI. Laurent completed his studies with a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics at the State University of New York at Buffalo (SUNY Buffalo). Nanobiotix was created as a spinoff based on the findings from his post-doctoral thesis.
Visit website: https://www.nanobiotix.com/nanobiotix-management-team/
Mentioned in this Resource
Laurent Levy News
Pharmashots interviews Laurent Levy about cancer-killing radiotherapy enhancers
Pharmashots - 10-Aug-2022
NBTXR3 might give hope to patients who are ineligible for certain chemotheraphyRead more...